Drug Trial Radar · NCT05142592
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Nov 15, 2021
Primary completion
Feb 8, 2026
Study completion Mar 5, 2026
Sponsor
- Lead sponsor
- Nanjing Immunophage Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single agent to patients with advanced solid tumors. The study will include a dose escalation phase (Phase 1) and a dose expansion phase (Phase 2a). Each part will consist of a screening period of up to 28 days, a treatment period, an end of treatment visit and a safety follow-up of approximately 30 days after the last dose. IPG7236 will be given on an empty stomach (either one hour before or two hours after a meal) twice daily (approximately every 12±1 hours) in continuous 28-day cycles.
Conditions
- Safety Issues
- Tolerability
- Pharmacokinetics
Interventions
IPG7236Drug
The IPG7236 drug product is supplied as oral tablet dosage form, containing two strengths: 25 mg and 100 mg, respectively, which contain IPG7236.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of all adverse eventsTime frame: Up to 33 days
- Maximum tolerated dose (MTD)Time frame: Up to 33 days
- Phase II dose (RP2D)Time frame: Up to 33 days
- Disease Control Rate(DCR)Time frame: up to 1 year(anticipated)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Providence Portland Medical Center
Portland, Oregon
NEXT Oncology
Austin, Texas
Shanghai East Hospital
Shanghai, China
Shanghai General Hospital
Shanghai, China
Shanghai GoBroad Cancer Hospital China Pharmaceutical University
Shanghai, China
The First Affiliated Hospital Nanchang Univeristy
Nanchang, Jiangxi, China
Shandong Cancer Hospital
Jinan, Shangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.